Odyssey Therapeutics, Inc.
ODTX
Get informed when a big investor buys or sells
+ FollowMarket Cap$639.94M
Close$
$-1.10
105.3% downside
Current Fair Value
105.3% downsideOvervalued by 105.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $639.94 Million |
|---|---|
| Enterprise Value | $630.35 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-5.39 |
| Beta | 1.43 |
| Outstanding Shares | 47,174,156 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -3.93 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | -1.73 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | -0.05 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
June 17, 2026
EPS Estimate
$-0.83
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$-1.10
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Odyssey Therapeutics, Inc.
100 employees
CEO: Gary D. Glick Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases. Its diverse pipeline features several key drug candidates: OD-001, an ...